These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33485644)

  • 1. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
    Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
    Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
    Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
    Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
    Baisley K; Kemp TJ; Mugo NR; Whitworth H; Onono MA; Njoroge B; Indangasi J; Bukusi EA; Prabhu PR; Mutani P; Galloway DA; Mwanzalime D; Kapiga S; Lacey CJ; Hayes RJ; Changalucha J; Pinto LA; Barnabas RV; Watson-Jones D
    Lancet Glob Health; 2024 Mar; 12(3):e491-e499. PubMed ID: 38365419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of antibody response to HPV vaccination in HIV infected girls].
    Ołdakowska A; Marczyńska M; Dobosz S; Stańska-Perka A; Popielska J; Szczepańska-Putz M
    Przegl Epidemiol; 2012; 66(4):651-5. PubMed ID: 23484395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
    Hidalgo-Tenorio C; Pasquau J; Omar-Mohamed M; Sampedro A; López-Ruz MA; López Hidalgo J; Ramírez-Taboada J
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
    Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
    Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
    Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
    Bhatla N; Muwonge R; Malvi SG; Joshi S; Poli URR; Lucas E; Esmy PO; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Vashist S; Mishra G; Jadhav R; Siddiqi M; Anantharaman D; Panicker G; Butt J; Sankaran S; Kannan TPRA; Varghese R; Kartha P; Pillai MR; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P
    Hum Vaccin Immunother; 2023 Dec; 19(3):2289242. PubMed ID: 38078840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.
    McClymont E; Ogilvie G; Albert A; Johnston A; Raboud J; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein MB; Harris M; Wobeser W; Bitnun A; Kakkar F; Samson L; Brophy J; Karatzios C; Money D;
    Vaccine; 2020 Mar; 38(15):3073-3078. PubMed ID: 32147300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.